Navigation Links
Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
Date:8/5/2008

Clinical study planned for advanced or recurrent solid tumors

PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1105, for the treatment of patients with selected advanced or recurrent solid tumors, specifically renal cell carcinoma, melanoma, non-small cell lung cancer or epithelial ovarian cancer. MDX-1105 is a fully human antibody that targets the PD-L1 pathway to promote enhanced T-cell immune responses against cancer and reverse T-cell inactivation in chronic infectious disease.

The open-label, multi-dose, dose-escalation Phase 1 clinical trial is expected to enroll up to 46 patients with selected advanced or recurrent solid tumors. This trial is designed to establish and evaluate the safety, tolerability and maximum tolerated dose, as well as preliminary pharmacodynamics and efficacy, of MDX-1105.

"We are pleased that another product candidate from our proprietary pipeline has progressed into clinical trials," said Howard H. Pien, President and CEO of Medarex. "We believe that our fully human anti-PD-1 and anti-PD-L1 antibodies represent the next stage in immunotherapy beyond the anti-CTLA-4 antibodies. We look forward to exploring the potential of MDX-1105 as a possible new treatment option for patients with cancer and infectious disease."

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 Today, ... central nervous system stimulant indicated for the treatment ... patients beginning Summer 2015. The ... received approval from the U.S. Food and Drug ... an extended-release formulation of methylphenidate capsule with an ...
(Date:5/22/2015)... May 22, 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the ... interim chief executive officer Howie Rosen will ... financial officer Tim Morris will be presenting ... two presentations are as follows: Jefferies 2015 ...
(Date:5/21/2015)... , May 21, 2015  When Ryan ... the side of his neck, he figured ... a couple weeks off from weight lifting. ... away.                               A series ... was referred to Michel Kliot, MD ...
Breaking Medicine Technology:Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4
... Company, Limited (hereafter, Daiichi Sankyo), announced today that the ... (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 ... Welfare in Japan. Edoxaban, which is being ... anticoagulant that specifically, reversibly and directly inhibits the enzyme, ...
... Ontario, April 21, 2011 Valeant Pharmaceuticals International, Inc. ... the following statement to shareholders of Cephalon, Inc. (NASDAQ: ... today, the Cephalon Board of Directors stated that it ... Company,s alternatives and options – and is focused on ...
Cached Medicine Technology:Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 2Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 3Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 4Valeant Pharmaceuticals Responds to Cephalon Board's Letter 2Valeant Pharmaceuticals Responds to Cephalon Board's Letter 3Valeant Pharmaceuticals Responds to Cephalon Board's Letter 4
(Date:5/22/2015)... (PRWEB) May 22, 2015 Bryce Henson, ... Anaheim Fit Body Boot Camp, recently accepted his program’s ... quickly after the launch of his location evidences the ... Anaheim community. , Fit Body Boot Camp is the ... camp franchise with hundreds of locations across North America, ...
(Date:5/22/2015)... 2015 Yisrayl Hawkins, Pastor and Overseer at ... new letter calling on religious leaders to make changes in ... published on his blog, discusses the history of war, how ... stop it. Yisrayl says mankind was created to lead peaceful, ... today’s society. , “Yahweh created mankind, according to His ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 India Network ... and developmental projects in rural India. India Network Visitor ... community projects that continues to help hundreds and thousands ... to sponsor a music concert by famous playback singer ... the Hindu Society of Central Florida activities. ...
(Date:5/21/2015)... WellCare Health Plans, Inc. (NYSE: WCG) announced today that its ... Kids Corporation (FHKC) to continue to provide managed care services ... Florida Healthy Kids (FHK) program. Pending execution, the two-year contract ... for two additional years at FHKC’s discretion. , Staywell will ... who live in Regions 1, 2, 3, 4, 5, 8, ...
(Date:5/21/2015)... 2015 Ticket Down is a reliable source for ... vs. Guatemala on Friday, July 3rd at LP Field in ... a fan of international soccer. The number of chances to watch ... soil is growing at a large clip. Over the past several ... the USA to play in front of the American people. The ...
Breaking Medicine News(10 mins):Health News:Healthy Living Brought to Anaheim— New Fitness Boot Camp Acquires 100 Clients 2Health News:Yisrayl Hawkins Calls on All Religions to Wake Up and Make Drastic Changes to End Suffering in New Letter 2Health News:India Network Visitor Health Insurance Announces Corporate Sponsorship of Anuradha Paudwal Musical in Orlando to Help Fundraise for Hindu Society of Central Florida. 2Health News:WellCare Selected to Continue Participating in the Florida Healthy Kids Program, Will Serve Nine Florida Regions Under the New Contract 2Health News:USA vs. Guatemala Tickets: Ticket Down Slashes United States Men's Soccer Team (USMNT) vs. Guatemala Tickets at LP Field in Nashville on 7/3/15 2
... much more than// allergens from dust mites or pets. ... Health Sciences, US, said that incidence of allergens from ... areas of the cities. ,The researchers had ... found out that there seems to be a significant ...
... People who have been suffering from chronic lower back pain ... surgical spine fusion. This is done when no other treatment ... recent study in the British Medical Journal reveled that in ... procedure for people who do not have enough finance to ...
... have reportd that exposure to pesticides may raise the ... is exposed to the pesticides the highre are his ... about 3000 people in Europan countries who either have ... and exposed to risk factors like pesticides. Researchers say ...
... College of Medicine brought to light that injecting ceramide// into ... breast cancer cells. ,Ceramide is a natural substance ... used to get better results out of breast cancer treatments. ... ,However injecting ceramide in the usual way into ...
... said in a new study that there’s adequate proof that ... of the elderly frequenting the bathroom more. ,Researchers had ... voiding flow rate and detrusor contraction strength from 95 females ... happens is that functionality of the bladder and the urethra ...
... found out that sex differences in sleep patterns do exist, ... had carried out a national survey of 39,588 people of ... city of Taiwan. The researchers considered several factors other than ... ,The results of the study had shown that there ...
Cached Medicine News:
An enzyme linked immunoassay (ELISA) for the detection and semiquantitationof IgG and IgM antibodies to 2-GP1, as an aid in assessingthe risk of thrombosis in patients with Systemic Lupus Erythematos...
An enzyme linked immunoassay (ELISA) for the detection and semiquantitation of IgG, IgA or IgM anticardiolipin antibodies, as an aid in assessing the risk of thrombosis in individuals with Systemic L...
The ImagingPlanet 70 mm surgical microscope video adapter: superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Zeiss surgical...
The ImagingPlanet 55 mm surgical microscope video adapter: superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Leica surgical ...
Medicine Products: